-

10:04:22 AM

AGEN Stock News

AGEN - Agenus Inc

08/09/22 8:00 AM

Nasdaq : AGEN

earnings

Agenus Provides Corporate Update and Second Quarter 2022 Financial Report

Botensilimab (Fc-enhanced CTLA-4)/balstilimab (PD-1) combination data presented at the 2022 ESMO World GI Congress demonstrated remarkable clinical activity in microsatellite stable colorectal cancer (MSS CRC) Agenus expects to present additional botensilimab expansion cohort data at upcoming

RHEA-AI

neutral

08/02/22 8:30 AM

Nasdaq : AGEN

conferences

Agenus to Participate at BTIG Biotechnology Conference

Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the Company will attend the BTIG Biotechnology Conference. Agenus

RHEA-AI

neutral

08/01/22 8:30 AM

Nasdaq : AGEN

clinical trial

Agenus Announces First Patient Dosed in Phase 1 Study of AGEN1571 (anti-ILT2) in Advanced Solid Tumors

Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company

RHEA-AI

neutral

07/27/22 8:30 AM

Nasdaq : AGEN

earnings

Agenus to Provide Corporate Update and Second Quarter 2022 Financial Report

Agenus (NASDAQ: AGEN) an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced it will

RHEA-AI

neutral

06/30/22 8:30 AM

Nasdaq : AGEN

conferences

Agenus to Participate at William Blair’s Biotech Focus Conference

Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced that Dr. Steven O’Day, Chief Medical Officer, will participate in a

RHEA-AI

neutral

06/29/22 7:00 AM

Nasdaq : AGEN

Agenus Shows Unprecedented Activity for Botensilimab/Balstilimab Combination in Microsatellite Stable Colorectal Cancer at ESMO World GI Congress

Overall response rate of 24%, and disease control rate of 73%, in heavily pre-treated patients with a median of 4 prior lines of therapy Responses to botensilimab/balstilimab were durable, with 80% ongoing at data cut-off and median duration of response not reached Global, randomized Phase 2 study

RHEA-AI

positive

06/21/22 8:30 AM

Nasdaq : AGEN

conferences

Agenus to Host Investor Webcast to Review Late-Breaking Botensilimab and Balstilimab Data Presented at ESMO World GI Congress

Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the Company will host a hybrid webcast to discuss

RHEA-AI

neutral

06/10/22 8:00 AM

Nasdaq : AGEN

GSK’s RSV vaccine candidate for older adults, containing Agenus’ QS-21 STIMULON™ as part of GSK’s AS01 adjuvant, reports positive pivotal data supporting initiation of global regulatory submissions

First RSV vaccine candidate to show statistically significant and clinically meaningful efficacy in adults aged 60 years and above Third AS01 adjuvanted vaccine containing QS-21 STIMULON to deliver meaningful clinical benefit against infections in a registrational program Global regulatory

RHEA-AI

neutral

05/31/22 8:30 AM

Nasdaq : AGEN

Agenus Advances Portfolio with 6 Clinical Collaborations

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced that it has entered into 3 new clinical collaborations with

RHEA-AI

very positive

05/25/22 8:30 AM

Nasdaq : AGEN

Agenus Announces Virtual Annual Shareholders Meeting

Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced that its Annual Shareholders Meeting will begin at 3:30 p.m. ET on

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

AGEN Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitewww.agenusbio.com
CeoGaro Armen
Security nameAgenus Inc
Issue typecs
SectorManufacturing
Sic code2836
Employees359
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
Address3 Forbes Rd
StateMassachusetts
CityLexington
Zip02421-7305
CountryUS
Phone17816744400

About Agenus Inc

Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA.